恩格列净对急性心肌梗死后心力衰竭患者的疗效和安全性

doi:10.3760/cma.j.issn.1007-1245.2024.18.024

摘要/Abstract

摘要：

目的　探究恩格列净对急性心肌梗死（AMI）后心力衰竭（HF）患者的疗效和安全性。方法　选取2022年6月至2024年1月景德镇市第一人民医院收治的72例AMI后HF患者，按随机数字表法分为两组，各36例。对照组男19例，女17例，年龄（62.18±6.19）岁，美国纽约心脏病学会（NYHA）分级Ⅱ级5例、Ⅲ级17例、Ⅳ级14例；恩格列净组男20例，女16例，年龄（62.33±6.21）岁，NYHA分级Ⅱ级6例、Ⅲ级18例、Ⅳ级12例。对照组行基础药物治疗，恩格列净组在此基础上加用恩格列净（10 mg/次，1次/d），治疗3个月。对比两组治疗效果、心功能指标［左心室射血分数（LVEF）、左心室收缩末期内径（LVESD）、左心室舒张末期内径（LVEDD）］、6 min步行距离（6MWD）、心血管不良事件、不良反应。采用χ²检验、t检验。结果　恩格列净组总有效率［91.67%（33/36）］高于对照组［72.22%（26/36）］（P<0.05）。治疗3个月后，两组LVEF、6MWD均升高，恩格列净组较对照组高，两组LVESD、LVEDD均降低，恩格列净组较对照组低（均P<0.05）。恩格列净组心血管不良事件发生率［5.56%（2/36）］低于对照组［22.22%（8/36）］（P<0.05）。恩格列净组不良反应总发生率［22.22%（8/36）］与对照组［19.44%（7/36）］比较，差异无统计学意义（P>0.05）。结论　恩格列净对AMI后HF患者有显著疗效，可改善患者心功能，降低心血管不良事件发生率，安全性较高。

关键词:

急性心肌梗死, 心力衰竭, 恩格列净, 心功能, 不良反应

Abstract:

Objective　To investigate the efficacy and safety of empagliflozin in patients with heart failure (HF) after acute myocardial infarction (AMI). Methods　A total of 72 patients with HF after AMI treated in Jingdezhen First People's Hospital from June 2022 to January 2024 were selected and were divided into two groups according to the random number table method, with 36 cases in each group. In the control group, there were 19 males and 17 females, aged (62.18±6.19) years, and the New York Heart Association (NYHA) grade was grade Ⅱ in 5 cases, grade Ⅲ in 17 cases, and grade Ⅳ in 14 cases. In the empagliflozin group, there were 20 males and 16 females, aged (62.33±6.21) years, including 6 cases of grade Ⅱ, 18 cases of grade Ⅲ, and 12 cases of grade Ⅳ. The control group was treated with basic drugs, and the empagliflozin group was additionally treated with empagliflozin (10 mg/time, once a day) for 3 months. The treatment effect, cardiac function indexes [left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESD), and left ventricular end-diastolic diameter (LVEDD)], 6-min walking distance (6MWD), cardiovascular adverse events, and adverse reactions were compared between the two groups. χ² test and t test were used. Results　The total effective rate of the empagliflozin group [91.67% (33/36)] was higher than that of the control group [72.22% (26/36)] (P<0.05). After 3 months of treatment, the LVEF and 6MWD were increased in both groups, which were higher in the empagliflozin group than in the control group; the LVESD and LVEDD were decreased in both groups, which were lower in the empagliflozin group than in the control group (all P<0.05). The incidence of cardiovascular adverse events in the empagliflozin group [5.56% (2/36)] was lower than that in the control group [22.22% (8/36)] (P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the empagliflozin group [22.22% (8/36)] and the control group [19.44% (7/36)] (P>0.05). Conclusion　Empagliflozin has significant efficacy in HF patients after AMI, which can improve the patients' cardiac function and reduce the incidence of cardiovascular adverse events, with high safety.

Key words:

Acute myocardial infarction, Heart failure, Empagliflozin, Heart function, Adverse reactions

石秀明彭金华何伟喜.

恩格列净对急性心肌梗死后心力衰竭患者的疗效和安全性 [J]. 国际医药卫生导报, 2024, 30(18): 3103-3106.

Shi Xiuming, Peng Jinhua, He Weixi.

Efficacy and safety of empagliflozin in patients with heart failure after acute myocardial infarction [J]. International Medicine and Health Guidance News, 2024, 30(18): 3103-3106.

参考文献

[1] 邵艳奇.冻干重组人脑利钠肽联合呋塞米治疗老年急性心肌梗死合并心力衰竭的临床研究[J].中西医结合心脑血管病杂志,2019,17(16):2480-2483. DOI:10.12102/j.issn.1672-1349.2019.16.022.
[2] Greene SJ, Bauersachs J, Brugts JJ, et al. Worsening heart failure: nomenclature, epidemiology, and future directions: JACC review topic of the week[J]. J Am Coll Cardiol, 2023, 81(4):413-424. DOI: 10.1016/j.jacc.2022.11.023.
[3] 陈君.重组人脑钠肽、沙库巴曲缬沙坦钠和托伐普坦序贯治疗老年AMI后HF患者的临床疗效观察[J].中国处方药,2022,20(7):83-85. DOI:10.3969/j.issn.1671- 945X.2022.07.033.
[4] 刘德平.钠-葡萄糖共转运蛋白2抑制剂在心力衰竭中的作用[J].中国心血管杂志,2020,25(1):1-3. DOI:10.3969/j.issn.1007-5410.2020.01.001.
[5] 陈静文,柳浦青.恩格列净对2型糖尿病合并射血分数保留的心力衰竭患者左心室舒张功能的影响[J].江苏医药,2023,49(4):402-404,408. DOI:10.19460/j.cnki.0253- 3685.2023.04.019.
[6] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南(2019)[J].中华心血管病杂志,2019,47(10):766-783. DOI:10.3760/cma.j.issn.0253-3758.2019.10.003.
[7] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789. DOI:10.3760/cma.j.issn.0253- 3758.2018.10.004.
[8] 覃松梅,邓艺新,刘航,等.6 min步行试验和评分量表评估COPD的预后[J].临床与病理杂志,2021,41(10):2395-2399. DOI:10.3978/j.issn.2095-6959.2021.10.025.
[9] 陈庆梅,朱成振,时军,等.冠状动脉内弹丸式注射水化肝素钠治疗急性心肌梗死病人PCI术中无复流的疗效及安全性观察[J].中西医结合心脑血管病杂志,2020,18(5):805-808. DOI:10.12102/j.issn.1672-1349.2020.05.025.
[10] 盛雪,纪征,王兆翔,等.达格列净联合诺欣妥对急性心肌梗死患者急诊介入治疗后心力衰竭的疗效[J].实用医学杂志,2022,38(11):1410-1414. DOI:10.3969/j.issn.1006-5725. 2022.11.020.
[11] Del Buono MG, Moroni F, Montone RA, et al. Ischemic cardiomyopathy and heart failure after acute myocardial infarction[J]. Curr Cardiol Rep, 2022, 24(10):1505-1515. DOI: 10.1007/s11886-022-01766-6.
[12] 刘侃玲,张瑶.达格列净对老年急性心肌梗死后心力衰竭患者心功能及MACE的影响[J].解放军医学杂志,2023,48(12):1427-1432. DOI:10.11855/j.issn.0577-7402. 2162.2023.0523.
[13] 潘丽华,孙国位,黄竹君,等.恩格列净联合rhBNP治疗对射血分数降低型心力衰竭患者心室重构和血清NT-proBNP、hs-CRP、IL-6水平的影响[J].临床和实验医学杂志,2023,22(18):1934-1938. DOI:10.3969/j.issn.1671-4695. 2023.18.009.
[14] 刘侃玲,张瑶.达格列净早期使用对老年急性心肌梗死后心力衰竭患者急性期心功能及炎症因子的影响[J].中国临床研究,2023,36(10):1518-1523. DOI:10.13429/j.cnki.cjcr.2023.10.016.
[15] James S, Erlinge D, Storey RF, et al. Dapagliflozin in myocardial infarction without diabetes or heart failure[J]. NEJM Evid, 2024, 3(2):EVIDoa2300286. DOI: 10.1056/EVIDoa2300286.
[16] 包丽雯,李勇.SGLT2抑制剂恩格列净心血管保护作用及研究——EMPA-HEART Cardiolink 6研究简评[J].中国糖尿病杂志,2019,27(7):557-560. DOI:10.3969/j.issn.1006- 6187.2019.07.016.
[17] 万一鸣,桑海强,董建增,等.恩格列净治疗射血分数降低的心力衰竭的药物经济学评价[J].中国药房,2022,33(1):74-78. DOI:10.6039/j.issn.1001-0408.2022.01.13.
[18] 杨贵宝,张艳,王一凡,等.恩格列净治疗射血分数轻度降低的心力衰竭的效果及对患者免疫炎症、氧化应激、心肌微循环的影响[J].海南医学,2024,35(6):767-771. DOI:10.3969/j.issn.1003-6350.2024.06.002.
[19] 陈芯荛,于长青,殷建,等.恩格列净对急性心肌梗死患者心功能和外周血单核细胞极化的影响[J].重庆医学,2023,52(16):2471-2476. DOI:10.3969/j.issn.1671-8348. 2023.16.013.
[20] 叶志强.达格列净在急性心肌梗死后心力衰竭患者中的应用效果[J].中外医学研究,2023,21(32):18-21. DOI:10.14033/j.cnki.cfmr.2023.32.005.
[21] 李雪博,范燕宾,杜睿,等.达格列净、恩格列净及卡格列净在心肌梗死后预防心力衰竭患者的临床研究[J].中国临床药理学杂志,2023,39(22):3204-3208. DOI:10.13699/j.cnki.1001-6821.2023.22.003.
[22] 曾智勇,蒋琰,周琼,等.恩格列净联合沙库巴曲缬沙坦治疗射血分数保留的心力衰竭患者的临床研究[J].中国临床药理学杂志,2023,39(21):3048-3052. DOI:10.13699/j.cnki.1001-6821.2023.21.002.
[23] 李远翥,罗素新,黄毕.钠-葡萄糖协同转运蛋白2抑制剂对射血分数保留型心力衰竭的治疗进展[J].中国心血管病研究,2023,21(8):757-762. DOI:10.3969/j.issn.1672-5301. 2023.08.015.
[24] 李永光,徐伟泽,魏钧伯,等.恩格列净保护心肌及调控线粒体功能的机制研究[J].医学综述,2022,28(8):1463-1467. DOI:10.3969/j.issn.1006-2084.2022.08.002.
[25] 张帆,陈丽,曹旭东,等.恩格列净上调沉默信息调节因子1减轻心肌缺血再灌流损伤[J].安徽医科大学学报,2022,57(8):1195-1200. DOI:10.19405/j.cnki.issn1000-1492. 2022.08.004.
[26] 魏煜迪,罗圣贺,金红花.恩格列净及达格列净对棕榈酸诱导的心肌细胞损伤的保护作用及其机制[J].中国现代应用药学,2023,40(20):2884-2890. DOI:10.13748/j.cnki.issn1007-7693.20223273.